NTLA vs VRTX
NTLA and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $1.75B | $141.70B |
| P/E (TTM) | — | 32.6 |
| P/B | — | 7.00 |
| P/S | 25.8x | 11.8x |
| Revenue | — | $12.59B(TTM) |
| Revenue growth (YoY) | 16.9% | 8.9% |
| Net income | — | $4.41B(TTM) |
| Earnings growth (YoY) | 20.5% | 838.1% |
| EPS, diluted | — | $17.17(TTM) |
| EBIT margin | -651.7% | 34.8% |
| ROE | -56.7% | 19.5% |
| ROIC | — | 25.0% |
| 1y total return | +1.6% | +33.1% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: NTLA vs VRTX
| 지표 | NTLA | VRTX |
|---|---|---|
| 최종 가치 | $5.5K | $65.8K |
| 총수익률 | -45.1% | +557.5% |
| CAGR | -5.6% | +20.0% |
| 변동성 | 78.3% | 32.6% |
| 샤프 | 0.26 | 0.60 |
| 소르티노 | 0.39 | 0.88 |
| 최대 낙폭 | -96.5% | -41.6% |
공통 거래일 2600일 기준, 2016-06-29 → 2026-10-30 · 무위험수익률 4.16% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)